Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9251705 | 0.91 | RAB9A (0.53) | NPY5RRAB9AALOX5ALDH1A1KMT2A | |
| SCHEMBL3523965 | 0.85 | MAPT (0.64) | RAB9AALDH1A1KMT2ANPC1MAPT | |
| SCHEMBL27857467 | 0.81 | NPY5R (0.57) | NPY5RRAB9AALOX5ALDH1A1KMT2A | |
| SCHEMBL13646415 | 0.80 | NPC1 (0.73) | NPY5RRAB9AALOX5ALDH1A1KMT2A | |
| SCHEMBL12297577 | 0.80 | KDM4E (0.76) | NPY5RRAB9AALDH1A1KMT2ANPC1 | |
| SCHEMBL28580508 | 0.79 | KMT2A (0.67) | NPY5RRAB9AALOX5ALDH1A1KMT2A | |
| SCHEMBL4590880 | 0.78 | KMT2A (0.59) | NPY5RRAB9AALOX5ALDH1A1KMT2A | |
| SCHEMBL4590653 | 0.78 | ALOX5 (0.56) | RAB9AALOX5ALDH1A1KMT2ANPC1 | |
| SCHEMBL4742175 | 0.77 | KMT2A (0.59) | NPY5RRAB9AALOX5ALDH1A1KMT2A | |
| SCHEMBL3918661 | 0.76 | GAA (0.58) | NPY5RRAB9AALOX5ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| CN-101208328-B | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | SANOFI AVENTIS | 2012-02-29 | — | — | CN | disclosed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
| CN-101208328-A | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-06-25 | — | — | CN | disclosed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | NPY5R 441/4885RAB9A 3899/4885ALOX5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.